Addition Of Everolimus To Exemestine Provides Sustained Survival Edge In Women With A

[News]

SAN ANTONIO - The survival benefit seen with everolimus plus exemestane over exemestane alone at 7.5 months and 12.5 months in women with advanced breast cancer is maintained at 18- month follow-up, investigators announced at the San Antonio Breast Cancer Symposium (SABCS)...

More... (http://www.medicalnewstoday.com/articles/253898.php)